These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1652239)

  • 1. Antigenic variation of pseudorabies virus glycoproteins g II and g III demonstrated by neutralizing monoclonal antibodies.
    Yamada S; Imada T; Nishimori T; Sekikawa K; Shimizu M
    Arch Virol; 1991; 119(3-4):285-90. PubMed ID: 1652239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of glycoproteins of pseudorabies virus in eliciting neutralizing antibodies.
    Ben-Porat T; DeMarchi JM; Lomniczi B; Kaplan AS
    Virology; 1986 Oct; 154(2):325-34. PubMed ID: 2429441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of protective immunity and neutralizing antibodies to pseudorabies virus by immunization of anti-idiotypic antibodies.
    Tsuda T; Onodera T; Sugimura T; Murakami Y
    Arch Virol; 1992; 124(3-4):291-300. PubMed ID: 1318708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping and characterization of neutralizing epitopes of glycoproteins gIII and gp50 of the Indiana-Funkhauser strain of pseudorabies virus.
    Coe NE; Mengeling WL
    Arch Virol; 1990; 110(1-2):137-42. PubMed ID: 1689995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the pseudorabies virus glycoprotein gp50 as a major target of neutralizing antibodies.
    Eloit M; Fargeaud D; L'Haridon R; Toma B
    Arch Virol; 1988; 99(1-2):45-56. PubMed ID: 2833202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudorabies virus glycoprotein gI: in vitro and in vivo analysis of immunorelevant epitopes.
    Fuchs W; Rziha HJ; Lukàcs N; Braunschweiger I; Visser N; Lütticken D; Schreurs CS; Thiel HJ; Mettenleiter TC
    J Gen Virol; 1990 May; 71 ( Pt 5)():1141-51. PubMed ID: 1693164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of mice and swine from pseudorabies virus-induced mortality by administration of pseudorabies virus-specific mouse monoclonal antibodies.
    Marchioli C; Yancey RJ; Timmins JG; Post LE; Young BR; Povendo DA
    Am J Vet Res; 1988 Jun; 49(6):860-4. PubMed ID: 2840843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and mapping of a nonessential pseudorabies virus glycoprotein.
    Wathen MW; Wathen LM
    J Virol; 1986 Apr; 58(1):173-8. PubMed ID: 3005646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The porcine humoral immune response against pseudorabies virus specifically targets attachment sites on glycoprotein gC.
    Ober BT; Teufel B; Wiesmüller KH; Jung G; Pfaff E; Saalmüller A; Rziha HJ
    J Virol; 2000 Feb; 74(4):1752-60. PubMed ID: 10644346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A complement-dependent neutralizing monoclonal antibody against glycoprotein II of pseudorabies virus.
    Nakamura T; Ihara T; Nagata T; Ishihama A; Ueda S
    Vet Microbiol; 1990 Aug; 24(2):193-8. PubMed ID: 2173250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of antigenic sites on pseudorabies virus glycoprotein gp50 implicated in virus penetration of the host cell.
    Eloit M; Bouzghaia H; Toma B
    J Gen Virol; 1990 Sep; 71 ( Pt 9)():2179-83. PubMed ID: 1698927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunological characteristics of Aujeszky's disease virus glycoprotein].
    Vrublevskaia VV; Musienko VS; Skarga IuIu; Morenkov OS
    Vopr Virusol; 2007; 52(3):33-7. PubMed ID: 17601050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the antigenic variability of pseudorabies virus field isolates with monoclonal antibodies.
    Matisová J; Lesko J; Gallo J; Subr Z; Sabo A
    Acta Vet Hung; 1994; 42(2-3):343-6. PubMed ID: 7810429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of mice from lethal infection with Aujeszky's disease virus by immunization with purified gVI.
    Ishii H; Kobayashi Y; Kuroki M; Kodama Y
    J Gen Virol; 1988 Jun; 69 ( Pt 6)():1411-4. PubMed ID: 2838579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of protective viral glycoproteins for pseudorabies virus infection.
    Matsuda A; Okada N; Katayama S; Okabe T; Sasaki N
    J Vet Med Sci; 1991 Aug; 53(4):737-41. PubMed ID: 1657214
    [No Abstract]   [Full Text] [Related]  

  • 16. Characterization of several pseudorabies viral strains by virus-neutralization test using monoclonal antibodies.
    Nosetto EO; Echeverria MG; Horimoto T; Pecoraro MR; Galosi CM; Tohya Y; Norimine J; Takahashi E; Etcheverrigaray ME; Mikami T
    Viral Immunol; 1997; 10(3):159-64. PubMed ID: 9344338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation of mutants of Aujeszky's disease virus with antigenically altered glycoprotein E by affinity chromatography using monoclonal antibodies.
    Morenkov OS; Smirnov SV; Vrublevskaya VV
    J Virol Methods; 1999 Jan; 77(1):101-8. PubMed ID: 10029330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation of gE gene deleted pseudorabies virus by using a gE specific monoclonal antibody.
    Chang AC; Pan MJ; Lee SC
    J Virol Methods; 1996 Jun; 60(1):19-28. PubMed ID: 8795002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of pseudorabies virus glycoprotein B expressed by canine herpesvirus.
    Nishikawa Y; Xuan X; Kimura M; Otsuka H
    J Vet Med Sci; 1999 Oct; 61(10):1113-7. PubMed ID: 10563288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of glycoprotein gII ISCOMs subunit vaccine for pseudorabies in pig.
    Tsuda T; Sugimura T; Murakami Y
    Vaccine; 1991 Sep; 9(9):648-52. PubMed ID: 1659053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.